NASDAQ:IDYA

IDEAYA Biosciences (IDYA) Stock Forecast, Price & News

$27.71

-0.48 (-1.70%)

(As of 02:10 PM ET)

Compare

Today's Range: $27.68
▼
$28.29
50-Day Range: $21.07
▼
$29.77
52-Week Range: $11.04
▼
$30.25

Volume: 126,298 shs
Average Volume: 539,049 shs
Market Capitalization: $1.59 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $32.08

IDEAYA Biosciences MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 15.8% Upside
$32.08 Price Target
Short Interest: Bearish
13.28% of Float Sold Short
Dividend Strength: N/A
Sustainability: -0.62
Upright™ Environmental Score
News Sentiment: 0.88
Based on 6 Articles This Week
Insider Trading: Selling Shares
$827,735 Sold Last Quarter
Proj. Earnings Growth: Decreasing
From ($2.01) to ($2.61) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.16 out of 5 stars

Medical Sector

510th out of 968 stocks

Pharmaceutical Preparations Industry

221st out of 445 stocks

3.5

Analyst's Opinion

Consensus Rating
IDEAYA Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 14 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $32.08, IDEAYA Biosciences has a forecasted upside of 15.8% from its current price of $27.71.
Amount of Analyst Coverage
IDEAYA Biosciences has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

0.0

Short Interest

Percentage of Shares Shorted
13.28% of the float of IDEAYA Biosciences has been sold short.
Short Interest Ratio / Days to Cover
IDEAYA Biosciences has a short interest ratio ("days to cover") of 13.5, which indicates bearish sentiment.
Change versus previous month
Short interest in IDEAYA Biosciences has recently increased by 4.45%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
IDEAYA Biosciences does not currently pay a dividend.
Dividend Growth
IDEAYA Biosciences does not have a long track record of dividend growth.

4.8

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
IDEAYA Biosciences has received a 77.45% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Preclinical research services for physical health" and "Clinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for IDEAYA Biosciences is -0.62.

3.8

News and Social Media Coverage

News Sentiment
IDEAYA Biosciences has a news sentiment score of 0.88. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 6 news articles for IDEAYA Biosciences this week, compared to 3 articles on an average week.
Search Interest
4 people have searched for IDYA on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.
MarketBeat Follows
4 people have added IDEAYA Biosciences to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, IDEAYA Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $827,735.00 in company stock.
Percentage Held by Insiders
Only 5.10% of the stock of IDEAYA Biosciences is held by insiders.
Percentage Held by Institutions
98.29% of the stock of IDEAYA Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for IDEAYA Biosciences are expected to decrease in the coming year, from ($2.01) to ($2.61) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of IDEAYA Biosciences is -19.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of IDEAYA Biosciences is -19.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
IDEAYA Biosciences has a P/B Ratio of 3.82. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About IDEAYA Biosciences (NASDAQ:IDYA) Stock

IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase II clinical trial for patients with solid tumors having methylthioadenosine phosphorylase gene deletions; and IDE196, a protein kinase C inhibitor that is in Phase I/II clinical trial for genetically defined cancers having GNAQ or GNA11 gene mutations. Its preclinical pipeline includes various synthetic lethality programs targeting PARG inhibitor in tumors for patients having tumors with a defined biomarker based on genetic mutations and/or molecular signatures; Pol Theta inhibitors in tumors with BRCA or other homologous recombination deficiency mutations; and WRN inhibitors in tumors with high microsatellite instability. The company has a research collaboration agreement with Cancer Research UK and the University of Manchester todevelop small molecule inhibitors of Poly (ADP-ribose) glycohydrolase; and a clinical trial collaboration and supply agreement with Pfizer Inc. for Phase II/III study in metastatic uveal melanoma, as well as a strategic partnership with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

IDYA Price History

30 days | 90 days | 365 days | Advanced Chart

IDYA Stock News Headlines

September 16, 2023 | americanbankingnews.com

Equities Analysts Issue Forecasts for IDEAYA Biosciences, Inc.'s Q1 2024 Earnings (NASDAQ:IDYA)

September 15, 2023 | finance.yahoo.com

Insider Sell: Chief Legal Officer Jason Throne Sells 1,000 Shares of IDEAYA Biosciences Inc

September 22, 2023 | UNKNOWN (Ad)

Bringing Space Down to Earth

Cutting edge, AI-powered, Space-based Earth-observation solutions

September 15, 2023 | americanbankingnews.com

Wedbush Comments on IDEAYA Biosciences, Inc.'s FY2027 Earnings (NASDAQ:IDYA)

September 15, 2023 | americanbankingnews.com

Leerink Partnrs Analysts Raise Earnings Estimates for IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

September 13, 2023 | americanbankingnews.com

IDEAYA Biosciences (NASDAQ:IDYA) Price Target Raised to $37.00

September 13, 2023 | msn.com

Goldman Sachs Maintains Ideaya Biosciences (IDYA) Buy Recommendation

September 13, 2023 | msn.com

Wedbush Maintains Ideaya Biosciences (IDYA) Outperform Recommendation

September 22, 2023 | Behind the Markets (Ad)

Laser breakthrough could send stock soaring 2,467%

Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...

September 13, 2023 | americanbankingnews.com

Wedbush Increases IDEAYA Biosciences (NASDAQ:IDYA) Price Target to $43.00

September 12, 2023 | markets.businessinsider.com

7 Analysts Have This to Say About IDEAYA Biosciences

September 11, 2023 | finance.yahoo.com

IDEAYA Announces Phase 1 Expansion and Preliminary Clinical Proof-of-Concept for Potential First-in-Class PARG Inhibitor IDE161 in HRD Solid Tumors

September 5, 2023 | prnewswire.com

IDEAYA Biosciences to Participate in Upcoming September 2023 Investor Relations Events

August 31, 2023 | msn.com

Ideaya Biosciences (IDYA) Price Target Increased by 6.31% to 35.78

August 20, 2023 | finance.yahoo.com

Broker Revenue Forecasts For IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Are Surging Higher

August 18, 2023 | nasdaq.com

JP Morgan Maintains Ideaya Biosciences (IDYA) Overweight Recommendation

August 14, 2023 | markets.businessinsider.com

Stifel Nicolaus Sticks to Its Buy Rating for IDEAYA Biosciences (IDYA)

August 12, 2023 | msn.com

RBC Capital Maintains Ideaya Biosciences (IDYA) Outperform Recommendation

August 12, 2023 | msn.com

Oppenheimer Maintains Ideaya Biosciences (IDYA) Outperform Recommendation

August 11, 2023 | msn.com

Ideaya Biosciences: Eye Cancer Therapy Drives Gains - More Upside Ahead

August 11, 2023 | markets.businessinsider.com

The Latest Analyst Ratings for IDEAYA Biosciences

August 10, 2023 | msn.com

IDEAYA Biosciences, Inc. (IDYA) Reports Q2 Loss, Lags Revenue Estimates

August 10, 2023 | finance.yahoo.com

IDEAYA Biosciences, Inc. Reports Second Quarter 2023 Financial Results and Provides Business Update

August 9, 2023 | msn.com

SVB Leerink Initiates Coverage of Ideaya Biosciences (IDYA) with Outperform Recommendation

August 2, 2023 | finance.yahoo.com

IDEAYA and Amgen Achieve First-Patient-In for Clinical Evaluation of IDE397 (MAT2A) and AMG 193 (PRMT5(MTA)) Combination in MTAP(-/-) Tumors

August 1, 2023 | finance.yahoo.com

IDEAYA Biosciences to Participate in Upcoming August 2023 Investor Relations Event

June 22, 2023 | finance.yahoo.com

IDEAYA Announces First Reported Case of Uveal Melanoma Patient Spared Enucleation in Phase 1 Neoadjuvant IST with Darovasertib Monotherapy

See More Headlines

Receive IDYA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for IDEAYA Biosciences and its competitors with MarketBeat's FREE daily newsletter.

IDYA Company Calendar

Last Earnings: 8/10/2023
Today: 9/22/2023
Next Earnings (Estimated): 11/14/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:IDYA
CUSIP: N/A
CIK: 1676725
Web: www.ideayabio.com
Phone: (650) 443-6209
Fax: N/A
Employees: 116
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $32.08
High Stock Price Forecast: $43.00
Low Stock Price Forecast: $24.00
Forecasted Upside/Downside: +13.8%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 14 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.45)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-58,650,000.00
Net Margins: -164.25%
Pretax Margin: -164.25%
Return on Equity: -19.09%
Return on Assets: -17.54%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 19.81
Quick Ratio: 19.80

Sales & Book Value

Annual Sales: $50.93 million
Price / Sales: 31.86
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $7.26 per share
Price / Book: 3.88

Miscellaneous

Outstanding Shares: 57,560,000
Free Float: 54,623,000
Market Cap: $1.62 billion
Optionable: Not Optionable
Beta: 0.75

7 Stocks to Buy And Hold Forever

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

Mr. Yujiro S. Hata (Age 49)
Co-Founder, Pres, CEO & Director
Comp: $851.7k

Dr. Michael A. White Ph.D. (Age 57)
Chief Scientific Officer
Comp: $613.85k

Dr. Darrin M. Beaupre M.D. (Age 56)
Ph.D., Chief Medical Officer
Comp: $152.64k

Dr. Jeffrey Hager Ph.D. (Age 58)
Co -Founder

Mr. Paul A. Stone J.D. (Age 59)
Chief Financial Officer

Mr. Andres Ruiz Briseno CPA (Age 37)
Principal Accounting Officer, Sr. VP and Head of Fin. & Investor Relations

Dr. Paul A. Barsanti Ph.D.
Chief Technology Officer

Mr. Jason S. Throne Esq. (Age 51)
J.D., Chief Legal Officer & Company Sec.

Dr. Matthew Maurer M.D.
VP and Head of Medical Affairs & Clinical Oncology

Mr. Mick O'Quigley
Sr. VP of Devel. Operations

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

IDYA Stock - Frequently Asked Questions

Should I buy or sell IDEAYA Biosciences stock right now?: 14 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for IDEAYA Biosciences in the last year. There are currently 14 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" IDYA shares.
View IDYA analyst ratings or view top-rated stocks.
What is IDEAYA Biosciences' stock price forecast for 2023?: 14 equities research analysts have issued 1 year price targets for IDEAYA Biosciences' shares. Their IDYA share price forecasts range from $24.00 to $43.00. On average, they predict the company's share price to reach $32.08 in the next year. This suggests a possible upside of 13.8% from the stock's current price.
View analysts price targets for IDYA or view top-rated stocks among Wall Street analysts.
How have IDYA shares performed in 2023?: IDEAYA Biosciences' stock was trading at $18.17 at the beginning of the year. Since then, IDYA shares have increased by 55.1% and is now trading at $28.19.
View the best growth stocks for 2023 here.
When is IDEAYA Biosciences' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023.
View our IDYA earnings forecast.
How were IDEAYA Biosciences' earnings last quarter?: IDEAYA Biosciences, Inc. (NASDAQ:IDYA) issued its quarterly earnings data on Thursday, August, 10th. The company reported ($0.50) EPS for the quarter, beating the consensus estimate of ($0.55) by $0.05. The company earned $3.50 million during the quarter, compared to the consensus estimate of $4.89 million. IDEAYA Biosciences had a negative net margin of 164.25% and a negative trailing twelve-month return on equity of 19.09%. The business's revenue for the quarter was down 55.7% on a year-over-year basis.
What ETFs hold IDEAYA Biosciences' stock?: ETFs with the largest weight of IDEAYA Biosciences (NASDAQ:IDYA) stock in their portfolio include Jacob Forward ETF (JFWD), Invesco Dorsey Wright Healthcare Momentum ETF (PTH) and ALPS Medical Breakthroughs ETF (SBIO).iShares Micro-Cap ETF (IWC).
What other stocks do shareholders of IDEAYA Biosciences own?: Based on aggregate information from My MarketBeat watchlists, some companies that other IDEAYA Biosciences investors own include Aldeyra Therapeutics (ALDX), Fulcrum Therapeutics (FULC), OPKO Health (OPK), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Boeing (BA), Xeris Biopharma (XERS), Entasis Therapeutics (ETTX), Livongo Health (LVGO) and NVIDIA (NVDA).

When did IDEAYA Biosciences IPO?: (IDYA) raised $70 million in an initial public offering on Thursday, May 23rd 2019. The company issued 5,000,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan, Citigroup and Jefferies served as the underwriters for the IPO.
What is IDEAYA Biosciences' stock symbol?: IDEAYA Biosciences trades on the NASDAQ under the ticker symbol "IDYA."
Who are IDEAYA Biosciences' major shareholders?: IDEAYA Biosciences' stock is owned by a number of retail and institutional investors. Top institutional shareholders include BVF Inc. IL (9.87%), BlackRock Inc. (7.60%), State Street Corp (3.72%), Dimensional Fund Advisors LP (1.90%), Geode Capital Management LLC (1.79%) and Platinum Investment Management Ltd. (1.42%). Insiders that own company stock include Jason Throne, Mark Lackner, Michael P Dillon, Michael P Dillon, Paul A Stone and Ventures Iv LP 5Am.
View institutional ownership trends.
How do I buy shares of IDEAYA Biosciences?: Shares of IDYA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is IDEAYA Biosciences' stock price today?: One share of IDYA stock can currently be purchased for approximately $28.19.
How much money does IDEAYA Biosciences make?: IDEAYA Biosciences (NASDAQ:IDYA) has a market capitalization of $1.62 billion and generates $50.93 million in revenue each year. The company earns $-58,650,000.00 in net income (profit) each year or ($1.45) on an earnings per share basis.
How many employees does IDEAYA Biosciences have?: The company employs 116 workers across the globe.
How can I contact IDEAYA Biosciences?: IDEAYA Biosciences' mailing address is 7000 SHORELINE COURT SUITE 350, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.ideayabio.com. The company can be reached via phone at (650) 443-6209 or via email at investor@ideayabio.com.

This page (NASDAQ:IDYA) was last updated on 9/22/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial